Endpoints for randomized controlled clinical trials for COVID-19 treatments.

Lori E Dodd Dean A FollmannJing WangFranz KoenigLisa L KornChristian SchoergenhoferMichael ProschanSally HunsbergerTyler BonnettMat MakowskiDrifa BelhadiYeming WangBin CaoFrance MentreThomas F Jaki

Published in: Clinical trials (London, England) (2020)

Time-to-event analysis methods have advantages in the COVID-19 setting, unless the optimal time for evaluating treatment effect is known in advance. Even when the optimal time is known, a time-to-event approach may increase power for interim analyses.

Keyphrases

coronavirus disease
sars cov
clinical trial
double blind
open label
phase ii
phase iii
placebo controlled
respiratory syndrome coronavirus
randomized controlled trial
combination therapy
replacement therapy
data analysis